Reports Q2 revenue $96.042M, consensus $91.96M. “With the approval of VYJUVEK in Europe and Japan, we are on the cusp of a global expansion that will build on our U.S. sales momentum and dramatically expand VYJUVEK access to DEB patients around the world,” said Krish S. Krishnan, Chairman and CEO of Krystal Biotech (KRYS). “At the same time, we are rapidly approaching key readouts in both the lung and eye. Success in these tissues would be transformational for Krystal, with profound implications for the versatility of our platform and for patients in need.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Is KRYS a Buy, Before Earnings?
- Positive Phase 1 Trial Results for KB304 Bolster Buy Rating for Krystal Biotech Amidst Promising Market Potential
- Krystal Biotech Gains Approval for DEB Treatment in Japan
- Krystal Biotech announces approval of VYJUVEK by Japan’s MHLW
- Promising Phase 1 Results and Market Potential Drive Buy Rating for Krystal Biotech